Medorekkusu

4586.TTSE GROWTHPharmaceutical

Filed as Medrx Co.,Ltd. (2022-08–2026-08)

Key numbers · FY ended 2025-12

Revenue¥128m-50.3% YoY Operating income−¥942m—Net income (owners)−¥937m—Total assets¥2.2bn-5.2% YoY EPS (basic)¥-17.44+6.0% YoY

Full financial history and reports →

Stock price4586 · View chart ↗

Open the price chart on TradingView.

Latest filings

Wed, Oct 7 · JST1 filing

16:055% STAKEMedorekkusu · Growth Capital Inc. · 8.54% → 6.15%−2.39pp

Tue, Sep 29 · JST1 filing

16:055% STAKEMedorekkusu · Growth Capital Inc. · 9.55% → 8.54%−1.01pp

Tue, Sep 15 · JST1 filing

15:405% STAKEMedorekkusu · Growth Capital Inc. · 10.77% → 9.55%−1.22pp

Mon, Aug 31 · JST1 filing

16:005% STAKEMedorekkusu · Growth Capital Inc. · 11.90% → 10.77%−1.13pp

Thu, Aug 13 · JST1 filing

16:005% STAKEMedorekkusu · Growth Capital Inc. · 13.70% → 11.90%−1.80pp

All filings →

Major holders (5%+) · 2

Holder	Stake	Change	Filed
Matsumura Yonehiro	10.57%	—	2024-06-10
Growth Capital Inc.	6.15%	-2.39pp	2026-10-07

Each holder's own ratio from its most recent large-shareholding report.